ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Parkinson’s Patients Seek Multidistrict Litigation Status for Growing Number of Paraquat-Exposure Lawsuits

Fears Nachawati trial lawyers: Single court is best for mass litigation

Chevron Phillips Chemical Co (NYSE: CVX)

These lawsuits are a critical step toward answering important questions about how this was allowed to happen and to make sure the damage caused by paraquat has stopped.”
— Trial Lawyer Bryan Fears
SAN FRANCISCO, CA, UNITED STATES, April 13, 2021 /EINPresswire.com/ -- Trial lawyers representing a growing number of people diagnosed with Parkinson’s disease after exposure to paraquat-based herbicides have asked a federal judicial panel to consolidate their lawsuits under a single federal court. The request comes as new filings by the Fears Nachawati Law Firm bring the number of federal lawsuits to more than 20.

Grouping the lawsuits as multidistrict litigation (MDL) cuts duplication and would allow the lawsuits to proceed more efficiently, said Fears Nachawati co-founder Majed Nachawati. The legal team has asked the federal Joint Panel on Multidistrict Litigation (JPML) to consolidate the cases with Judge Edward Chen in the U.S. District Court for the Northern District of California.

“With a progressive neurological disease like Parkinson’s, there’s no time to lose,” said Mr. Nachawati. “The efficiencies of multidistrict litigation cut duplication and provide the fastest way for these individuals to achieve justice.”

Similar lawsuits have been filed in California, Illinois, Wisconsin, Arkansas, Maryland, Missouri and West Virginia by individuals diagnosed with the neurodegenerative disorder after exposureto paraquat products like Gramoxone. The lawsuits name Gramoxone-maker Syngenta (SZSE: 000553) and Chevron Phillips Chemical Co., which manufactured and sold Gramoxone. Chevron Phillips Chemical Co., better known as CPChem, is a 50-50 joint venture between Chevron (NYSE: CVX) and Phillips 66 (NYSE: PSX).

Paraquat’s dangers have been documented for decades. The chemical is deadly if even a small amount is swallowed. Medical studies have established links between paraquat and Parkinson’s, an incurable and progressive brain disorder that leads to tremors, stiffness, and difficulty with walking, balance and coordination.

“For too long, these companies have knowingly exposed tens of thousands of unsuspecting Americans to a chemical so deadly that it has been banned in more than 50 countries,” said Fears Nachawati trial lawyer Bryan Fears. “These lawsuits are a critical step toward answering important questions about how this was allowed to happen and to make sure the damage caused by paraquat has stopped.”

The case is In Re: Paraquat Products Liability Litigation, MDL No. 3004.

Dallas-based Fears | Nachawati Law Firm represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation, and individual victims in complex personal injury litigation. For the past three years, the law firm was ranked No. 1 nationally in product liability filings in federal court. For more information, visit https://www.fnlawfirm.com.

John Raggio
Fears Nachawati
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.